Context CEO Martin Lehr Named Finalist for EY Young Entrepreneur of The Year® in Greater Philadelphia
PHILADELPHIA, PA, Sept. 01, 2020 — Context Therapeutics, a clinical-stage biopharmaceutical company dedicated to advancing medicines for hormone driven cancers, today announced that its CEO, Martin Lehr, has been named finalist for the Ernst & Young LLP (EY US) Young Entrepreneur of the Year 2020 Award in the Greater Philadelphia area. The award honors entrepreneurial business leaders whose ambitions deliver innovation, growth and prosperity as they build and sustain successful businesses that transform our world. Award winners will be announced through a special virtual event in early October.
“I am sincerely honored to be named a finalist for the EY Entrepreneur of the Year and to represent our terrific company, our talented team, our inspiring patients, and all the innovative entrepreneurs and scientists in this great region,” said Lehr. I thank EY for this honor and its support of entrepreneurs in Greater Philadelphia and throughout the world.”
About EY Entrepreneur of the Year
Entrepreneur of The Year is one of the preeminent competitive award programs for entrepreneurs and leaders of high-growth companies. The nominees are evaluated based on six criteria: overcoming adversity; financial performance; societal impact and commitment to building a values-based company; innovation; and talent management. Since its launch, the program has expanded to recognize business leaders in more than 145 cities in over 60 countries around the world.
Founded and produced by Ernst & Young LLP, the Entrepreneur of The Year Awards are nationally sponsored by SAP America and the Kauffman Foundation. In Greater Philadelphia, sponsors also include PNC Bank, DFIN, SolomonEdwards Group, Ballard Spahr LLP, Morgan, Lewis & Bockius LLP, Murray Devine & Company and Pepper Troutman LLP.
About Onapristone Extended Release
ONA-XR (onapristone extended release) is a potent and specific antagonist of the progesterone receptor that is orally administered. Currently, there are no approved therapies that selectively target PR+ cancers. Preliminary preclinical and clinical data suggest that ONA-XR has anticancer activity by inhibiting progesterone receptor binding to chromatin, downregulating cancer stem cell mobilization and blocking immune evasion. ONA-XR is currently the subject of an ongoing Phase 2 clinical trial in progesterone receptor positive ovarian cancer. Additional Phase 2 clinical trials in breast and endometrial cancers will initiate in 2020. ONA-XR is an investigational drug that has not been approved for marketing by any regulatory authority.
About Context Therapeutics®
Context Therapeutics LLC is a clinical-stage biopharmaceutical company advancing medicines to treat hormone driven cancers. Context’s lead program is ONA-XR, an investigational Phase 2 drug that is being developed for progesterone receptor positive (PR+) breast, ovarian and endometrial cancers. For more information on Context, visit www.contexttherapeutics.com.
Company Contact:
Martin Lehr
Co-Founder & Chief Executive Officer
info@contexttherapeutics.com
Media Contact:
Heather Anderson
6 Degrees
980-938-0260
handerson@6degreespr.com
Source: Context Therapeutics LLC